Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Optimal Long Term Treatment Strategy of Anti-resorptive Medications
Sponsor: National Taiwan University Hospital
Summary
This study is to investigate whether the alternating use of Prolia (Denosumab) and Aclasta (Zoledronic acid) can continue to increase bone density.
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2021-11-20
Completion Date
2030-12-31
Last Updated
2025-05-22
Healthy Volunteers
No
Conditions
Interventions
Continuous Denosumab
Active comparator: persistent treatment of denosumab.
Administer zoledronate and denosumab on an alternating schedule
In the experimental group, zoledronic acid was administered for one year, followed by two years of denosumab. This cycle was repeated, with the regimen concluding with one year of zoledronic acid.
Locations (1)
National Taiwan University Hospital, Yunlin branch
Douliu, Yunlin county, Taiwan